|
1
|
Avoidance of serious ADRs
|
12
|
21,400
|
256,800
|
Quality/safety improved
|
|
2
|
Transvenous antimicrobial therapy interventions
|
172
|
1900
|
325,080
|
Pharmacotherapy improved
|
|
3
|
Switch from intravenous to oral administration
|
Voriconazole
|
55
|
165.1
|
9078
|
Cost saving
|
|
Linezolid
|
32
|
96.9
|
3099
|
|
4
|
Interventions concerning cancer chemotherapy
|
82
|
1120
|
91,840
|
Pharmacotherapy improved
|
|
5
|
Avoidance of drug interactions
|
High risk
|
2
|
840
|
1680
|
Pharmacotherapy improved
|
|
Normal
|
56
|
560
|
31,360
|
|
6
|
Renal dosing recommendations
|
High risk
|
7
|
840
|
5880
|
Pharmacotherapy improved
|
|
Normal
|
43
|
560
|
24,080
|
|
7
|
Intravenous drug compatibility
|
High risk
|
1
|
840
|
840
|
Pharmacotherapy improved
|
|
Normal
|
2
|
560
|
1120
|
|
8
|
Confirmation of medication history (presurgical cessation of antiplatelet drugs)
|
High risk
|
13
|
840
|
10,920
|
Quality/safety improved
|
|
Normal
|
4
|
560
|
2240
|
|
9
|
Drug therapy consultation or recommendations
|
High risk
|
34
|
840
|
285,60
|
Pharmacotherapy improved
|
|
Normal
|
149
|
560
|
834,40
|
|
10
|
Monitoring recommendations
| |
19
|
0
|
0
|
Pharmacotherapy improved
|
|
11
|
Ward rounds, multidisciplinary teamwork
|
ICT
|
28
|
0
|
0
|
Quality/safety improved
|
|
NST
|
45
|
0
|
0
|
|
PCT
|
52
|
0
|
0
|
|
12
|
Drug information
| |
640
|
0
|
0
|
Provider education
|
|
13
|
ADRs reported to PMDA
|
4
|
0
|
0
|
Quality/safety improved
|
| |
Total
|
1452
|
-
|
876,017
| |
